Participants in the study will be given either hydrocortisone in the form of an oral tablet or a placebo. Following the initial administration of the medication, participants will be monitored over a period of time. This involves completing various questionnaires to report on their experiences and symptoms, as well as providing samples such as saliva. Additionally, some participants may use wearable devices to track their heart rate and heart rate variability, which refers to the variation in time between each heartbeat.

The study consists of two parts. In the first part, researchers will examine how childhood difficulties affect the body’s stress system in people with PTSD. In the second part, some participants will receive either hydrocortisone tablets (20 mg) or a placebo to see if the medication can help them learn to feel safe in situations that previously caused fear responses.

During the study, participants will provide saliva samples to measure stress hormones and undergo various assessments in a safe environment using virtual reality technology. Some participants will also have brain scans to help researchers understand how the treatment affects brain activity. The medication is taken by mouth in the form of tablets, and the study includes regular check-ups to monitor participants’ well-being.

The purpose of the study is to evaluate whether taking Propranolol soon after experiencing trauma can reduce the occurrence of PTSD symptoms. The study will follow participants over a period of time to observe any changes in their symptoms. Participants will be asked to take the medication and attend follow-up visits where their symptoms will be assessed using questionnaires and scales designed to measure PTSD and overall functioning.

Throughout the study, participants will be monitored for any side effects or adverse events. The study aims to provide valuable information on whether Propranolol can be an effective early intervention for preventing PTSD in women who have experienced sexual violence. The results could potentially lead to new treatment options for those at risk of developing PTSD after traumatic events.

The purpose of the study is to assess how effective and safe Methylone is when used over a long period. Participants will receive either a single or repeated doses of Methylone over the course of the study. The study will last for 52 weeks, during which participants will be monitored to see how their symptoms change and to ensure their safety while taking the medication.

Throughout the study, various assessments will be conducted to measure the impact of Methylone on PTSD symptoms. These assessments will include evaluations of mental health, mood, and overall well-being. The study aims to provide valuable information on whether Methylone can be a beneficial treatment option for individuals living with PTSD.

Participants in the study will receive MDMA-assisted therapy in a high-intensity inpatient setting. This means that the treatment will be provided in a controlled environment where participants stay for a period of time to receive therapy. The study is designed to observe changes in PTSD symptoms over a specific period. Participants will be monitored and assessed to understand how the therapy impacts their condition.

The study aims to provide insights into whether MDMA-assisted therapy can be an effective treatment for individuals with PTSD who have not responded to other treatments. By participating in this study, researchers hope to gather valuable information that could lead to new treatment options for those affected by PTSD. The study will follow a structured course, but specific technical details are not included in this description.

The purpose of the study is to determine if mifepristone can help reduce the severity of PTSD symptoms in individuals who have not responded to other treatments. Participants in the study will take mifepristone for a period of seven days, with a daily dose of 1200 milligrams. The study will monitor changes in PTSD symptoms over several weeks to assess the medication’s effectiveness. The trial will involve regular assessments to track the progress of symptoms and any changes in the participants’ condition.

Throughout the study, participants will be evaluated using various tools to measure PTSD symptoms and other related factors such as sleep quality, stress levels, anxiety, and depression. The study will last for several months, with follow-up assessments to understand the long-term effects of the treatment. This research aims to provide new insights into managing treatment-resistant PTSD and improving the quality of life for those affected by this challenging condition.

The study aims to evaluate if methylone capsules taken by mouth can help reduce PTSD symptoms. During the study, participants will receive either methylone or placebo capsules. The treatment will be given once weekly over a period of 4 weeks, followed by additional monitoring to assess the effects.

The study is divided into two parts. The first part focuses on determining if the medication is safe and how well people tolerate it. The second part examines how effective the medication is at improving PTSD symptoms. Throughout the study, participants will have their health monitored through various assessments and medical examinations to ensure their safety and evaluate their response to the treatment.

Participants in the study will be divided into different groups. Some will receive prolonged exposure therapy combined with propranolol, while others will receive prolonged exposure therapy without propranolol. The goal is to determine if propranolol can help improve the outcomes of the therapy. The study will last for a period of up to six months, during which participants will take propranolol orally, in doses of either 10 mg or 40 mg, depending on the group they are in. The maximum daily dose will not exceed 80 mg.

The purpose of this study is to verify the effectiveness of these treatments in helping patients manage their PTSD symptoms. The trial will use various scales and measures to assess changes in symptoms, emotions, and overall well-being. By comparing the different treatment approaches, the study aims to provide valuable insights into how best to support individuals living with PTSD.

The medications being tested belong to a group of drugs called alpha-adrenergic agents, which can affect how the body responds to stress. During the study, participants will receive either clonidine (0.075-0.375 mg), doxazosin (1-10 mg), or placebo in the form of capsules. The treatment period lasts for several weeks, during which the medication dose may be adjusted.

Throughout the study, participants will have their nightmare frequency and intensity monitored, along with their overall PTSD symptoms and sleep quality. The study will also track changes in depression symptoms, daily sleep patterns, and quality of life. Regular check-ups will be conducted to monitor the participants’ progress and any potential effects of the medications.

The study involves participants who are Dutch uniformed personnel, such as police officers, firefighters, ambulance paramedics, military personnel, or veterans. Participants will take CBD capsules daily for two weeks. During this period, researchers will monitor changes in anxiety levels using a tool called Beck’s anxiety index. Additionally, the study will assess how CBD affects fear responses, stress regulation, and sleep quality. These assessments will involve questionnaires, physiological measurements, and a sleep watch to gather comprehensive data on the effects of CBD.

By examining these factors, the study aims to provide insights into whether CBD can be beneficial in managing anxiety symptoms and improving overall well-being before starting traditional therapy for anxiety or PTSD. The findings could potentially lead to new approaches in preparing individuals for therapy, enhancing their treatment outcomes.